Li Yue-Xi, Li Chao, Tao Kai-Hua, Jia Xiang-Hong, Cheng Du-Sheng, Huang Pei-Tang
East China Institute of Medical Biotechniques, Nanjing 210002, China.
Sheng Wu Gong Cheng Xue Bao. 2002 Jul;18(4):424-30.
Many antineoplastic agents can cause myelosuppression and thrombocytopenia. Thrombopoietin (TPO) is believed to be the major cytokine affecting the proliferation and maturation of megakaryocytes and increasing circulating platelet levels. We have designed and synthesized a TPO mimetic peptide, it can increase circulating platelet levels in vivo. For increasing half-life and forming dimer, the peptide was expressed as chimeric proteins with human IgG1 Fc fragments. The cDNA of TPO mimetic peptide was synthesized chemically and linked respectively to 5' terminus of human IgG1 Fc cDNA fragments in various length (Fc1: Fc 5' 648 bp; Fc2: Fc 5' 270 bp; Fc3: Fc 5' 267 bp; Fc4: Fc 5' 90 bp), and cloned into expression plasmid pET28a (+) for constructing four recombinant plasmids. By transforming the four recombinant plasmids into E. coli. BL21 (DE3) respectively, we got 3 kinds of engineered E. coli which express TPO + Fc chimeric proteins(28 kD TPO + Fc1, 12 kD TPO + Fc2 and 12 kD TPO + Fc3) at high level respectively, the expressed proteins were purified with DEAE-Sepharose FF and S-Sepharose FF column. The bioactivities of the expressed chimeric proteins(TPO + Fc1, TPO + Fc2 and TPO + Fc3), TPO mimetic peptide, and PEG4000 coupled TPO mimetic peptide were evaluated with Ba/F3-mp1 in vitro and with carboplatin-induced thrombocytopenia mice in vivo, the expressed chimeric proteins have higher activity than TPO mimetic peptide both in vitro and in vivo, the EC50 on Ba/F3-mp1 cells were 13, 10, 10, 50, and 25 nmol/L respectively, all of them can increase circulating platelet counts. Their imol/Lunogenicity were valuated in mice, none of them can elicit mice to produce antibodies to TPO mimetic peptide, meanwhile three TPO + Fc chimeric proteins can elicit mice to produce antibodies to human IgG1 Fc. These studies have laid basis for production of TPO mimetic peptide by genetic engineering.
许多抗肿瘤药物可导致骨髓抑制和血小板减少。血小板生成素(TPO)被认为是影响巨核细胞增殖和成熟以及提高循环血小板水平的主要细胞因子。我们设计并合成了一种TPO模拟肽,它可在体内提高循环血小板水平。为了延长半衰期并形成二聚体,该肽被表达为与人IgG1 Fc片段的嵌合蛋白。TPO模拟肽的cDNA通过化学合成,并分别连接到不同长度的人IgG1 Fc cDNA片段的5'末端(Fc1:Fc 5' 648 bp;Fc2:Fc 5' 270 bp;Fc3:Fc 5' 267 bp;Fc4:Fc 5' 90 bp),并克隆到表达质粒pET28a(+)中以构建四种重组质粒。通过将这四种重组质粒分别转化到大肠杆菌BL21(DE3)中,我们分别获得了3种能高水平表达TPO+Fc嵌合蛋白(28 kD TPO+Fc1、12 kD TPO+Fc2和12 kD TPO+Fc3)的工程大肠杆菌,表达的蛋白用DEAE-琼脂糖FF和S-琼脂糖FF柱进行纯化。用Ba/F3-mp1在体外以及用卡铂诱导的血小板减少小鼠在体内评估表达的嵌合蛋白(TPO+Fc1、TPO+Fc2和TPO+Fc3)、TPO模拟肽以及聚乙二醇4000偶联的TPO模拟肽的生物活性,表达的嵌合蛋白在体外和体内均比TPO模拟肽具有更高的活性,在Ba/F3-mp1细胞上的EC50分别为13、10、